Skip to main content

Cancer Drug Flushes Out HIV

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

HIV can evade treatment by hiding out within a patients’ own cells. Because they don’t always express tell-tale viral genes, the antiviral drugs cannot find and destroy them. But new research, published yesterday (July 25) in Nature, suggests that a cancer drug, known as vorinostat, may be the answer. After a single dose of vorinostat, which is used to treat certain types of lymphoma, patients experienced an almost 5-fold increase in HIV RNA expression

“HIV therapeutics is about to enter a new phase,” Steven Deeks of the University of California, San Francisco, wrote in an accompanying Nature commentary. “Over the past 25 years, the focus has been almost entirely on develop­ing and optimizing drugs aimed at inhibiting active HIV replication.” This has led to numerous antiretroviral therapies that turned HIV from a death sentence into a largely manageable disease. “But [these therapies] do not eliminate inactive viruses within cells,” Deeks ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile

Related Topics

Related articles background image
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni
Conceptual multicolored image of DNA helices.

Exploring the Most Impactful CRISPR Stories

Promega

Products

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform

Beckman Coulter Life Sciences Logo

Beckman Coulter Life Sciences Launches Vi-CELL BLU 2.0 Software to Advance Data Integrity and GMP Readiness in Cell Analysis